Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cardiff Oncology (CRDF) EBT (2016 - 2025)

Cardiff Oncology (CRDF) has disclosed EBT for 15 consecutive years, with -$7.2 million as the latest value for Q4 2025.

  • Quarterly EBT rose 38.78% to -$7.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$45.9 million through Dec 2025, down 1.02% year-over-year, with the annual reading at -$45.9 million for FY2025, 1.02% down from the prior year.
  • EBT hit -$7.2 million in Q4 2025 for Cardiff Oncology, up from -$11.3 million in the prior quarter.
  • In the past five years, EBT ranged from a high of -$5.4 million in Q1 2021 to a low of -$13.9 million in Q2 2025.
  • Historically, EBT has averaged -$10.1 million across 5 years, with a median of -$10.2 million in 2022.
  • Biggest five-year swings in EBT: crashed 103.49% in 2022 and later surged 38.78% in 2025.
  • Year by year, EBT stood at -$9.5 million in 2021, then increased by 1.41% to -$9.4 million in 2022, then rose by 0.72% to -$9.3 million in 2023, then decreased by 26.39% to -$11.8 million in 2024, then soared by 38.78% to -$7.2 million in 2025.
  • Business Quant data shows EBT for CRDF at -$7.2 million in Q4 2025, -$11.3 million in Q3 2025, and -$13.9 million in Q2 2025.